January Top 10: MAP Pharmaceuticals


In the following video, Motley Fool health-care analyst David Williamson takes a continuing look at the best-performing stocks in health care for this past January. In this video, he highlights MAP Pharmaceuticals , up 58% last month because of a buyout coming from its marketing partner, Allergan . In the video, David tells us why MAP's key product, an inhaled migraine medication called Levadex, could be an excellent synergistic win for Allergan even though the FDA rejected the drug last March, and why Allergan is much more than the company known for Botox.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article January Top 10: MAP Pharmaceuticals originally appeared on Fool.com.

David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.